The COVID-19 pandemic has been a global challenge that has impacted almost every aspect of life. The pandemic has presented unique challenges in Africa, including limited resources and infrastructure. However, Africa has faced similar challenges in the past with the Ebola outbreak, which has prepared the continent to respond to pandemics effectively. Leveraging Ebola preparedness for COVID-19 trials can enable pharmaceutical industry sponsors and researchers to complete time-sensitive COVID-19 clinical trials.
Importance of Leveraging Ebola Preparedness for COVID-19 trials.
The Ebola outbreak in West Africa in 2014-2016 presented a significant challenge, but it also served as a turning point in the continent’s preparedness for pandemics. The outbreak highlighted the need for the continent to build robust health systems and improve emergency preparedness and public health response. The lessons learned from the Ebola outbreak have become invaluable in Africa’s response to the COVID-19 pandemic. Leveraging Ebola preparedness for COVID-19 trials saves R&D time and money and improves clinical development.
Leveraging Ebola preparedness to conduct COVID-19 clinical trials in Africa requires several strategies.
1. Regulatory Framework
A robust regulatory framework for clinical trials during an outbreak is critical. This framework should include guidelines for ethical considerations, informed consent, and safety measures for participants. The framework was established for the Ebola vaccine and treatment research in the affected African Vaccine Regulatory Forum (AVAREF) countries to ensure that clinical trials are conducted according to international standards.
2. Leveraging Ebola Research Infrastructure
During the 2014 Ebola outbreak, infrastructure such as research institutions, laboratories, and clinical trial sites was developed. This infrastructure exists in areas where there is a high prevalence of COVID-19 and can be leveraged to enable efficient COVID-19 clinical trial operations. Additionally, there is a need to establish partnerships between local and international research institutions to leverage resources and expertise.
3. Community Engagement Structures
Community engagement should be prioritized to build trust between the researchers and the community. This trust is essential to ensure that clinical trials are conducted ethically and that participants are willing to participate. COVID-19 trials scan benefits from Ebola community engagement and sensitization mechanisms and strategies.
4. Leveraging Technology
There is a need to leverage Ebola technology to facilitate the conduct of COVID-19 clinical trials. Technology can be used for remote monitoring of participants, data collection, and analysis. This technology can help to reduce the cost and time required to conduct COVID-19 clinical trials.
5. Repurposing Ebola Training for COVID-19
The training received during the Ebola outbreak has equipped healthcare workers and researchers with the necessary skills to conduct clinical trials for COVID-19. Therefore, leveraging the Ebola preparedness training will play a critical role during the COVID-19 response, ultimately contributing to the global fight against the pandemic.
Download our FREE e-book today to learn more about how ACE Research is leveraging Ebola preparedness to conduct COVID-19 clinical trials.
